key: cord-0993913-iwj1ytup
authors: Chan, X.H.S.; O’Connor, C.J.; Martyn, E.; Clegg, A.J.; Choy, B.J.K.; Soares, A.L.; Shulman, R.; Stone, N.R.H.; De, S.; Bitmead, J.; Hail, L.; Brealey, D.; Arulkumaran, N.; Singer, M.; Wilson, A.P.R.
title: Comparison of Antibiotic Use between the First Two Waves of COVID-19 in an Intensive Care Unit at a London Tertiary Centre: reducing broad-spectrum antimicrobial use did not adversely affect mortality
date: 2022-03-23
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2022.03.007
sha: abded06ea0b1c470ddf4e88d4d173c422adf1d1b
doc_id: 993913
cord_uid: iwj1ytup

BACKGROUND: The COVID-19 pandemic increased the use of broad-spectrum antibiotics due to diagnostic uncertainty, particularly in critical care. Multiprofessional communication became more difficult, weakening stewardship activities. AIM: To determine changes in bacterial co-/secondary infections and antibiotics used in COVID-19 patients in critical care, and mortality rates, between the first and second waves. METHODS: Prospective audit comparing bacterial co-/secondary infections and their treatment during the first two waves of the pandemic in a single centre teaching hospital ICU. Data on demographics, daily antibiotic use, clinical outcomes, and culture results in patients diagnosed with COVID-19 infection were collected over 11 months. FINDINGS: From 9/3/20 to 2/9/20 (Wave 1), there were 156 patients and between 3/9/20 and 1/2/21 (Wave 2) there were 235 patients with COVID-19 infection admitted to intensive care. No significant difference was seen in mortality or positive blood culture rates between the two waves. The proportion of patients receiving antimicrobial therapy (93.0% vs 81.7%; p<0.01), and the duration of meropenem use (median (interquartile range): 5 (2-7) vs 3 (2-5) days; p=0.01) was lower in Wave 2. However, the number of patients with respiratory isolates of Pseudomonas aeruginosa (4/156 vs 21/235; p<0.01) and bacteraemia from a respiratory source (3/156 vs 20/235 p<0.01) increased in Wave 2, associated with an outbreak of infection. There was no significant difference between waves with respect to isolation of other pathogens. CONCLUSIONS: Reduced broad spectrum antimicrobial use in the second wave of COVID-19 compared with the first wave was not associated with significant change in mortality.

The COVID-19 pandemic increased the use of broad-spectrum antibiotics due to diagnostic 27 uncertainty, particularly in critical care. Multiprofessional communication became more 28 difficult, weakening stewardship activities. 29 30 Aim 31

To determine changes in bacterial co-/secondary infections and antibiotics used in COVID-19 32 patients in critical care, and mortality rates, between the first and second waves. The transition from first to second wave was taken as 3/9/20 which corresponded to a short 108 period of no COVID-19 infected admissions. In wave 2, an enhanced clinical pharmacy team 109 advised on individualised patient dosing based on pharmacokinetic-pharmacodynamic 110 principles. In contrast to wave 1, administration of meropenem was generally discouraged 111 and its use was de-escalated or stopped as soon as clinically indicated. 112 113 Patient demographics, daily antibiotic usage, microbiology culture results and clinical 114 outcomes were recorded prospectively as part of routine care. Missing results were found 115 retrospectively during audit using hospital electronic healthcare records. Bronchoalveolar 116 lavage was performed rarely due to concerns regarding aerosolization. From hospital 117 electronic health record and pathology systems, we collected data on all patients with a 118 clinical, and/or virologically confirmed diagnosis of COVID-19 admitted to the adult ICU 119 between 9/3/20 and 1/2/21. As we report data as part of service evaluation, ethics committee 120 permission was not sought. Patients were followed to discharge from ICU. 121 122 Individual patient-level data on demographics (age, sex, date of ICU admission), use of 123 antibiotics (generic name, days of treatment per 100 intensive care unit adjusted patient days 124 DOT/1000 ICU APD), treatment outcomes (death in or discharge from ICU) were recorded, 125 as well as positive cultures. The source of bacteraemia was determined by the clinical 126 assessment of the microbiology and ICU teams based on the clinical presentation, organism 127 isolated, and management instigated based on positive blood culture. Contaminants were 128 those that were thought not clinically significant at the time and did not require a clinical 129 intervention. Co-infections were defined as those diagnosed within two days of admission to 130

Continuous data were treated as non-parametric and reported as median (inter-quartile range), 134

with distributions compared using the Wilcoxon rank sum test with continuity correction. 135

Proportions were compared with Fisher's exact or Pearson's chi-squared test with Yates' 136 continuity correction as appropriate. p<0.05 was the threshold for statistical significance. All 137 statistical analyses and data visualisation were performed using R version 3.6.0. 138 139

Our adult ICU admitted a total of 391 COVID-19 patients between 9 March 2020 and 1 141

February 2021: 156 in Wave 1 (9/3/20-2/9/20) and 235 patients in Wave 2 (3/9/20-1/2/21). 142 ICU COVID-19 occupancy reached a peak of 54 in Wave 1 (≥50 from 12-18/4/2020) and 78 143

in Wave 2 (≥50 from 4/1/21-1/2/2021) (Figures 2A & B (Table I) . 150 151 Total antibiotic duration of 6 (2-11) days per patient did not differ between waves (p=0.66) 152 with at least one antibiotic given on 571 DOT/1000 ICU APD (Table II) . More patients were 153

given no antibiotic during their ICU stay in Wave 2 (Table I) . Short courses of anti-154 pseudomonal antibiotics, with median durations of antibiotic between 2 and 5 days during 155

given on 55 DOT/1000 ICU APD compared with 129 DOT/1000 ICU APD (p<0.01). As a 158 result, ceftazidime use unit-wide was significantly higher in Wave 2 (110 DOT/1000 ICU 159 APD) than Wave 1 (69 DOT/1000 ICU APD) (p<0.01). Co-amoxiclav and piperacillin-160 tazobactam use fell significantly in the second wave (p<0.01). Clarithromycin was not given 161 empirically in the second wave (Table II) (Table I) . 171

Only one significant positive blood culture in Wave 1 and eight from four patients in Wave 2 172 were co-infections (<48h of admission were caused by Gram-negative organisms. There was no significant difference in Gram-179 negative bacteraemia types overall between the two waves, the most common isolates being 180

Enterobacterales and Pseudomonas aeruginosa (Table I) . Escherichia coli was found in only 181 one week in January 2021 developed pseudomonas bacteraemia in an outbreak which 183 continued after 1 st February, three also having sputum isolates. These concomitant infections 184 accounted for 18 patient-days of antipseudomonal antibiotic treatment. However, the isolates 185

were not typed or sequenced. Only 5 patients overall had P. aeruginosa isolated from both 186 sputum and blood. Serratia spp. bacteraemia was identified in two patients in Wave 1 and six 187 in Wave 2. There was a cluster of Staphylococcus aureus pneumonia (four isolates in four 188 patients) in Wave 2, of which two isolates were found to be indistinguishable on multilocus 189 sequence typing. The only blood isolate of Streptococcus pneumoniae was in a patient with 190 pneumonia co-infection in wave 2. Only four patients had candidaemia and one had a 191 respiratory isolate of Aspergillus sp. in the whole period (Table II, when preliminary results were available on the day after the blood culture was taken. Another 209 3 (2.5%) patients had an increase in antimicrobial spectrum and two reduced (or stopped 210 antibiotic) on the second day after the blood culture was taken, when susceptibility 211 information was available. Treatment was changed within 24 hours of the blood culture from 212 piperacillin-tazobactam to meropenem on 6 occasions, to ciprofloxacin on two, and to 213 temocillin on one, either after clinical deterioration or previous microbiological results. 214

Bacterial pathogens at sites other than blood were similar in both waves (Table III) (Table I) . 219 220

In the year prior to the COVID-19 pandemic, critical care patients in our unit were 221 predominantly haematology, oncology, acute medical and surgical, in whom E. coli was the 222 most frequent cause of Gram-negative bacteraemia (Table IV) There are limitations to our study. These are results from a single centre and may not be 308 generalisable to other hospitals. Although demographic and antibiotic use data were collected 309 prospectively, some microbiological data were collected retrospectively. The data preceding 310 the pandemic was part of a national surveillance scheme (ICCQIP) and relates to a different 311 patient population in the ICU, in particular a high proportion of haematology/oncology 312 patients [7] . The data were not adjusted for confounders such as patient comorbidities and 313 duration of mechanical ventilation. No bacterial pathogens were isolated in many patients 314 treated with antibiotics. Days of antibiotic use have been collected rather than dose and 315

weight, but these are likely to be more reflective of usage than defined daily doses, which J o u r n a l P r e -p r o o f 

Bacteraemia incidence, 377 causative organisms and resistance patterns, antibiotic strategies and outcomes in a single 378 university hospital ICU: continuing improvement between 2000 and 2013

Surveillance of bloodstream infections in intensive care units in England

epidemiology and ecology

Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a 388 prospective observational study

Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients 393 hospitalised in intensive care unit

Defining COVID-19 associated pulmonary aspergillosis: systematic review and meta-398 analysis

J o u r n a l P r e -p r o o f